Caris Life Sciences, Inc. (CAI) Cash Flow Statement
Caris Life Sciences, Inc. (CAI) generated $168.6M of operating cash flow over the twelve months to 2026-06-30, spent $44.6M on capital expenditure and had free cash flow of $124.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAICaris Life Sciences, Inc.Follow CAI — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 85.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -0.28 | -0.25 | 0.08 | 0.17 | |
| Capital expenditure | 0.02 | 0.01 | 0.02 | -0.04 | |
| Free cash flow | -0.30 | -0.25 | 0.07 | 0.12 | |
| Share repurchases | 0.00 | 0.00 | 0.00 | — | |
| Stock-based compensation | 0.02 | 0.02 | 0.07 | — |
USD billions · SEC XBRL
Caris Life Sciences, Inc. — questions
- What is Caris Life Sciences, Inc.'s operating cash flow?
- $168.6M over the twelve months to 2026-06-30.
- How much does Caris Life Sciences, Inc. spend on capital expenditure?
- $44.6M over the twelve months to 2026-06-30.
- What is Caris Life Sciences, Inc.'s free cash flow?
- $124.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Caris Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.